Key terms

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest NBIX news

Yesterday 8:31am ET Neurocrine initiates Phase 1 study of NBI-1065890 Mar 20 7:03am ET Neurocrine price target raised to $158 from $148 at JPMorgan Mar 14 7:15am ET Maintaining Hold Rating for Neurocrine Biosciences Amid Reduced Competition and Long-Term Market Potential Mar 14 7:15am ET Strong Buy on Neurocrine Biosciences as Crinecerfont Leads in CAH Market, Backed by Solid Pipeline and Underappreciated Value Mar 14 6:20am ET Analysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH) Mar 13 7:23am ET Neurocrine price target raised to $200 from $170 at Oppenheimer Mar 01 8:40am ET Analysts Are Bullish on These Healthcare Stocks: Tenet Healthcare (THC), Moderna (MRNA) Feb 26 7:16am ET Voyager Therapeutics reports selection of gene therapy development candidate Feb 23 11:55am ET JPMorgan biotech analysts to hold an analyst/industry conference call Feb 23 11:00am ET JPMorgan biotech analysts to hold an analyst/industry conference call Feb 22 7:32am ET RBC Capital Keeps Their Hold Rating on Neurocrine (NBIX) Feb 20 7:31am ET Neurocrine price target raised to $159 from $128 at UBS Feb 13 5:41am ET Positive Outlook for Neurocrine Biosciences with Underappreciated Pipeline Potential Feb 12 7:57am ET Neurocrine price target raised to $164 from $157 at Guggenheim Feb 09 12:56am ET Neurocrine Biosciences: A Strong Buy on Robust Financial Performance and Promising Drug Pipeline Feb 09 12:51am ET Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Sarepta Therapeutics (SRPT) and Neurocrine (NBIX) Feb 08 8:59am ET Neurocrine price target raised to $161 from $160 at Deutsche Bank Feb 08 7:50am ET Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL) Feb 08 7:48am ET Oppenheimer Keeps Their Buy Rating on Neurocrine (NBIX) Feb 08 7:33am ET Neurocrine price target raised to $106 from $100 at Piper Sandler Feb 08 7:31am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS) and Neurocrine (NBIX) Feb 08 7:17am ET Neurocrine price target raised to $154 from $150 at Canaccord Feb 08 6:46am ET Neurocrine price target raised to $140 from $116 at Mizuho Feb 08 6:31am ET Analysts Offer Insights on Healthcare Companies: McKesson (MCK), Arcus Biosciences (RCUS) and Neurocrine (NBIX) Feb 08 6:27am ET Neurocrine (NBIX) Gets a Buy from Barclays Feb 08 6:17am ET Neurocrine price target raised to $140 from $127 at Wells Fargo Feb 08 6:16am ET Promising Pipeline and Market Positioning Underpin Buy Rating for Neurocrine’s Stock (NBIX) Feb 08 6:02am ET Analysts Conflicted on These Healthcare Names: McKesson (MCK), Arcturus Therapeutics (ARCT) and Neurocrine (NBIX) Feb 08 5:53am ET Neurocrine price target lowered to $140 from $141 at Citi Feb 08 5:30am ET Analysts Offer Insights on Healthcare Companies: Azenta (AZTA), Neurocrine (NBIX) and McKesson (MCK) Feb 07 6:35pm ET Neurocrine Biosciences Buy Rating Affirmed Amid Solid Ingrezza Growth and Promising Pipeline

No recent news articles are available for NBIX

No recent press releases are available for NBIX

NBIX Financials

1-year income & revenue

Key terms

NBIX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

NBIX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms